China Sxt Pharmaceuticals Stock Performance
| SXTC Stock | USD 0.99 0.19 16.10% |
The firm shows a Beta (market volatility) of 2.96, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, China SXT will likely underperform. China SXT Pharmaceuticals has an expected return of -0.43%. Please make sure to confirm China SXT Pharmaceuticals potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if China SXT Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days China SXT Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in May 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Last Split Factor 1:25 | Last Split Date 2023-10-05 |
1 | China SXT Pharmaceuticals, Inc. Sees Significant Increase in Short Interest | 02/14/2024 |
2 | China SXT Pharmaceuticals Inc Down 2.08 percent in Premarket Trading - InvestorsObserver | 02/28/2024 |
3 | Financial Contrast Northwest Biotherapeutics vs. China SXT Pharmaceuticals - Defense World | 03/04/2024 |
4 | 12 Health Care Stocks Moving In Wednesdays Intraday Session - Adial Pharmaceuticals , Dare - Benzinga | 04/17/2024 |
| Begin Period Cash Flow | 15.6 M |
China |
China SXT Relative Risk vs. Return Landscape
If you would invest 163.00 in China SXT Pharmaceuticals on January 20, 2024 and sell it today you would lose (64.00) from holding China SXT Pharmaceuticals or give up 39.26% of portfolio value over 90 days. China SXT Pharmaceuticals is currently does not generate positive expected returns and assumes 8.6488% risk (volatility on return distribution) over the 90 days horizon. In different words, 76% of stocks are less volatile than China, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
China SXT Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for China SXT's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as China SXT Pharmaceuticals, and traders can use it to determine the average amount a China SXT's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0497
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SXTC |
Estimated Market Risk
| 8.65 actual daily | 76 76% of assets are less volatile |
Expected Return
| -0.43 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average China SXT is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of China SXT by adding China SXT to a well-diversified portfolio.
China SXT Fundamentals Growth
China Stock prices reflect investors' perceptions of the future prospects and financial health of China SXT, and China SXT fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on China Stock performance.
| Return On Equity | -1.42 | ||||
| Return On Asset | -0.46 | ||||
| Operating Margin | (9.95) % | ||||
| Current Valuation | (7.17 M) | ||||
| Shares Outstanding | 565.53 K | ||||
| Price To Earning | 5.73 X | ||||
| Price To Book | 0.05 X | ||||
| Price To Sales | 0.46 X | ||||
| Revenue | 1.97 M | ||||
| Gross Profit | 1.25 M | ||||
| EBITDA | (5.36 M) | ||||
| Net Income | (5.93 M) | ||||
| Cash And Equivalents | 15.52 M | ||||
| Cash Per Share | 5.78 X | ||||
| Total Debt | 3.76 M | ||||
| Debt To Equity | 0.68 % | ||||
| Current Ratio | 1.31 X | ||||
| Book Value Per Share | 6.97 X | ||||
| Cash Flow From Operations | (80.76 K) | ||||
| Earnings Per Share | (26.95) X | ||||
| Market Capitalization | 559.88 K | ||||
| Total Asset | 29.55 M | ||||
| Retained Earnings | (21.61 M) | ||||
| Working Capital | 5.02 M | ||||
About China SXT Performance
To evaluate China SXT Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when China SXT generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare China Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand China SXT Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents China's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 112.93 | 126.00 | |
| Return On Tangible Assets | (0.23) | (0.22) | |
| Return On Capital Employed | (0.43) | (0.41) | |
| Return On Assets | (0.23) | (0.22) | |
| Return On Equity | (0.46) | (0.44) |
Things to note about China SXT Pharmaceuticals performance evaluation
Checking the ongoing alerts about China SXT for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for China SXT Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| China SXT generated a negative expected return over the last 90 days | |
| China SXT has high historical volatility and very poor performance | |
| China SXT has some characteristics of a very speculative penny stock | |
| China SXT has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.97 M. Net Loss for the year was (5.93 M) with profit before overhead, payroll, taxes, and interest of 1.25 M. | |
| China SXT Pharmaceuticals currently holds about 15.52 M in cash with (80.76 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| China SXT has a poor financial position based on the latest SEC disclosures | |
| Roughly 22.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: 12 Health Care Stocks Moving In Wednesdays Intraday Session - Adial Pharmaceuticals , Dare - Benzinga |
- Analyzing China SXT's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether China SXT's stock is overvalued or undervalued compared to its peers.
- Examining China SXT's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating China SXT's management team can have a significant impact on its success or failure. Reviewing the track record and experience of China SXT's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of China SXT's stock. These opinions can provide insight into China SXT's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for China Stock analysis
When running China SXT's price analysis, check to measure China SXT's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy China SXT is operating at the current time. Most of China SXT's value examination focuses on studying past and present price action to predict the probability of China SXT's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move China SXT's price. Additionally, you may evaluate how the addition of China SXT to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| CEOs Directory Screen CEOs from public companies around the world | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is China SXT's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China SXT listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.426 | Earnings Share (26.95) | Revenue Per Share 3.65 | Quarterly Revenue Growth (0.22) | Return On Assets (0.46) |
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China SXT's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.